Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals Strategy United States

Ipca Takes Full Ownership Of Bayshore

Strikes Deal To Acquire Remaining 20% Holding In US Generics Firm

  • News

Executive Summary

Ipca has struck a deal to take full ownership of US firm Bayshore Pharmaceuticals by acquiring the remaining 20% stake that it did not already own.

You may also be interested in...



Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate

In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.

Biosimilars Players Climb Global Rankings

Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.

Ipca Adds To API Business By Acquiring Ramdev

India’s Ipca is boosting its API business with a deal to acquire local firm Ramdev Chemical for INR1.1bn in cash.

Table

View full table

Related Content

Generics Bulletin

Topics

Related Companies

Tags:
Deals Strategy United States
Latest Headlines

Shortlist Revealed Ahead Of October Awards

Rani Takes Next Step As Oral Ustekinumab Biosimilar Enters The Clinic

Amneal Outlines Ambitions To Become Leading Affordable Medicines Supplier In US

Amgen: Regulatory Reform Must Not Tie The FDA’s Hands On Evaluating Biosimilarity

See All
UsernamePublicRestriction

Register

GB151295

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By